HER2-low
Patients With HER2-Low Early Breast Cancer Respond to Trastuzumab Deruxtecan
Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 ...
DECEMBER 28, 2022

Load more